Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CHMANASDAQ:GNPXNASDAQ:IMVOTCMKTS:LTUSNASDAQ:MTCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCHMAChiasma$3.76$4.01$2.77▼$5.74$217.68M1.282.12 million shs147 shsGNPXGenprex$0.26-1.2%$0.28$0.20▼$3.97$7.15M-0.54.16 million shs528,668 shsIMVIMV$0.66$0.48▼$12.70$9.63M0.95233,607 shs44,800 shsLTUSLotus Pharmaceuticals$0.01-4.3%$0.01$0.00▼$0.01$17.72M-2.4855,582 shs5,000 shsMTCRMetacrine$0.58$0.57$0.30▼$0.59$24.75M-0.73225,834 shs83,889 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCHMAChiasma0.00%0.00%0.00%0.00%0.00%GNPXGenprex0.00%+19.55%-8.55%-15.19%-86.16%IMVIMV0.00%0.00%0.00%0.00%0.00%LTUSLotus Pharmaceuticals0.00%-1.41%+40.00%+40.00%+112.12%MTCRMetacrine0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCHMAChiasmaN/AN/AN/AN/AN/AN/AN/AN/AGNPXGenprex1.0371 of 5 stars0.04.00.04.70.00.00.6IMVIMVN/AN/AN/AN/AN/AN/AN/AN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMTCRMetacrineN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCHMAChiasma 0.00N/AN/AN/AGNPXGenprex 0.00N/AN/AN/AIMVIMV 0.00N/AN/AN/ALTUSLotus Pharmaceuticals 0.00N/AN/AN/AMTCRMetacrine 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCHMAChiasma$1.11M196.11N/AN/A$1.59 per share2.36GNPXGenprexN/AN/AN/AN/A$0.15 per shareN/AIMVIMV$330K0.00N/AN/A($0.69) per share0.00LTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/AMTCRMetacrineN/AN/AN/AN/A$1.36 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCHMAChiasma-$74.78M-$1.43N/AN/AN/AN/A-113.57%-57.62%N/AGNPXGenprex-$21.11MN/A0.00N/AN/AN/A-664.65%-370.18%8/8/2025 (Estimated)IMVIMV-$37.99M-$4.59N/AN/AN/A-11,547.42%-12,695.41%-104.84%N/ALTUSLotus Pharmaceuticals$110KN/A0.00∞N/AN/AN/AN/AN/AMTCRMetacrine-$62.21M-$1.03N/A∞N/AN/A-84.88%-59.33%N/ALatest GNPX, LTUS, IMV, CHMA, and MTCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025GNPXGenprex-$0.82-$0.26+$0.56-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCHMAChiasmaN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/AIMVIMVN/AN/AN/AN/AN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AMTCRMetacrineN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCHMAChiasmaN/A7.917.08GNPXGenprexN/A1.941.94IMVIMVN/A2.932.93LTUSLotus PharmaceuticalsN/AN/AN/AMTCRMetacrine0.3412.1512.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCHMAChiasma61.68%GNPXGenprex14.05%IMVIMV15.37%LTUSLotus PharmaceuticalsN/AMTCRMetacrine37.72%Insider OwnershipCompanyInsider OwnershipCHMAChiasma8.30%GNPXGenprex8.47%IMVIMV0.33%LTUSLotus PharmaceuticalsN/AMTCRMetacrine13.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCHMAChiasma8557.89 millionN/ANot OptionableGNPXGenprex2027.82 million25.47 millionNo DataIMVIMV9711.71 million11.67 millionOptionableLTUSLotus Pharmaceuticals2302.64 billionN/ANot OptionableMTCRMetacrine1042.57 million36.70 millionNot OptionableGNPX, LTUS, IMV, CHMA, and MTCR HeadlinesRecent News About These CompaniesHypersonic missiles and weaponsNovember 12, 2024 | scmp.comU.S. sending powerful defense system to Israel, deepening its involvement in the conflictNovember 11, 2024 | nbcnews.comNorth Korea: 6 Experts on How We Can Solve the ProblemOctober 25, 2024 | time.comT'Iran made a big mistake': Israel promises revenge after missile attackOctober 4, 2024 | usatoday.comBest parental control app of 2024September 21, 2024 | techradar.comTUkraine summons Iranian diplomat as Tehran denies missile transfer to RussiaSeptember 11, 2024 | reuters.comRussia strikes Ukraine's power grid in 'most massive' attack of warAugust 28, 2024 | reuters.comUkraine-Russia war - latestAugust 22, 2024 | news.sky.comNCuban regime’s reported return to meddling in US elections a ‘badge of honor’ for targeted criticsAugust 1, 2024 | foxnews.comUS imposes new missile, drone-related sanctions on IranAugust 1, 2024 | en.mehrnews.comEClassroom TechnologyMay 19, 2024 | slu.eduSUS says China is boosting Russia's war machine in UkraineApril 17, 2024 | reuters.comArtesyn Expands ControlSafe™ SIL4 COTS Rail Computing Platform to Address More Train Control and Rail Signalling ApplicationsApril 15, 2024 | railway-technology.comRTrain Control Network Project for China RailApril 11, 2024 | railway-technology.comRUkraine-Russia war latest: NATO soldiers 'already present' in Ukraine; China, Russia and Iran to hold joint naval exercisesMarch 11, 2024 | news.sky.comNFormer engineer stole US-made missile technology to help China, federal agents sayFebruary 28, 2024 | courthousenews.comCTwitter says hackers downloaded private account dataDecember 20, 2023 | bbc.comBAN2 Therapeutics Inc ANTXNovember 9, 2023 | morningstar.comMMore Missiles for AsiaOctober 28, 2023 | thediplomat.comTIndia’s Armed Drone FleetOctober 21, 2023 | thediplomat.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNPX, LTUS, IMV, CHMA, and MTCR Company DescriptionsChiasma NASDAQ:CHMAChiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.Genprex NASDAQ:GNPX$0.26 0.00 (-1.23%) Closing price 04:00 PM EasternExtended Trading$0.25 0.00 (-1.59%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.IMV NASDAQ:IMVIMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.Lotus Pharmaceuticals OTCMKTS:LTUS$0.0067 0.00 (-4.29%) As of 10:24 AM EasternLotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.Metacrine NASDAQ:MTCRMetacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
